Neonatal respiratory distress syndrome, also referred to as infant respiratory distress syndrome is characterized by a particular condition often observed in premature babies, usually born about six weeks before their due dates. During this condition, lungs of the premature infants lose the ability to produce enough surfactants in order to provide oxygen to the body. Surfactants are liquids made up of fat and proteins and it helps the lungs to remain inflated so that infants can breathe in and out immediately after their birth. Hence, the prime cause for the prevalence of neonatal respiratory distress syndrome is the lack of surfactant in the lungs. Various signs and symptoms associated with neonatal respiratory distress syndrome are as follows:

Grunting respiration

Flaring nostrils

Cyanosis

Blue-colored lips, fingers and toes

Sharp pulling in the chest

Rapid breathing

Based on the treatments and mediations, the neonatal respiratory distress syndrome market can be segmented as follows:

Surfactant Replacement Therapy: The infants who suffer from respiratory distress syndrome are given surfactant through a breathing tube. Surfactants are administered until the lungs start to make the substance on their own.

Oxygen Therapy: Infants with severe breathing problems are given oxygen therapy through a ventilator or NCPAP machine, i.e., nasal continuous positive airway pressure. This therapy ensures that there is a sufficient supply of oxygen to the infant in order to breathe effectively.

Supportive Therapy: Supportive therapy helps the premature infants to meet their basic needs of nutrition and protection. For instance, use of incubator to keep the baby warm, and fluids and nutrients intake through needles inserted into the needle’s veins.

Other treatments: Other treatments include drugs and therapeutics to cure neonatal respiratory distress syndrome. Example, surfaxin (lucinactant), which was approved in March, 2012 by the U.S. Food and Drug Administration for the treatment of infant respiratory distress syndrome.

Based on geography, the neonatal respiratory distress market can be segmented into four major regions: North America, Europe, Asia Pacific and Rest of the World. Out of these regions, North America dominates the neonatal respiratory distress market followed by Europe. The prime reasons which have driven the growth of this market in these regions are high prevalence of respiratory disorders in infants and increasing genetic problems with lung development. According to a survey, neonatal respiratory distress syndrome is estimated to affect around 20,000-30,000 infants each year in the United States. Asia Pacific is the most promising market for the growth of neonatal respiratory distress syndrome market as there are many developing regions that are growing at a steady pace. The major factors which will propel the growth of this market in Asia Pacific are high birth rate, increasing awareness related to the complications of respiratory distress syndrome in infants and increasing pregnancy-induced hypertension due to malnutrition. Moreover, increasing incidences of premature labor and high-risk pregnancy in mothers would drive the Asian market towards future growth.

Many pharmaceutical companies and clinical trial institutes are constantly trying to come up with novel therapeutic development for the treatment of neonatal respiratory distress syndrome. Some of the leading players operating in the neonatal respiratory distress market are Chiesi Farmaceutici SpA, Discovery Laboratories, Inc., Takeda Pharmaceutical Company Limited, Auckland City Hospital, Menzies Research Institute and many others.

This research report analyzes this market on the basis of its market segments, major geographies, and current market trends. Geographies analyzed under this research report include

North America

Asia Pacific

Europe

Rest of the World

This report provides comprehensive analysis of

Market growth drivers

Factors limiting market growth

Current market trends

Market structure

Market projections for upcoming years

This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.

Upcoming Reports

Affinity chromatography, also known as bioselective adsorption, is a type of liquid chromatography for purification of a specific molecule or a group of molecules from complex mixtures. The fundamental principle comprising the method is the isolation...

The visualization of the larynx is done with a digital laryngoscope or fiber optic inserted transorally or transnasally. The images are recorded for a more detailed examination. Larynx examination can be performed by indirect laryngoscopy and direct ...

Different oral healthcare trackers are designed with different features, such as Oral Hygiene Device, which is designed with blue light which hits the teeth, they act as mirrors to reflect the light into the dental pocket between the gums, areas that...

Hearing loss can occurs when inner ear or nerve is damaged, which may be caused due to diseases, aging, loud noise, and medications. Hearing amplifier is a small part of hearing aid which makes the sound louder. Hearing amplifiers increase the power ...

A cardiac holter monitor is a battery operated device which continuously monitors the heart rhythm of the patient, for a period of 24-48 hours. The duration of measuring the activity of heart depends upon the type of device used, and the patient&rsqu...